Table 3 Demographics and clinical features of the patients divided for treatment with antifibrotic drugs
Variable | n | TREATMENT | p | |
|---|---|---|---|---|
NO N = 156 | YES N = 156 | |||
Gender | ||||
Female n (%) | 95 | 56 (35.9) | 39 (25) | 0.036 |
Male n (%) | 217 | 100 (64.1) | 117 (75) | |
Age at inclusion mean (SD) | 312 | 74.9 (8.7) | 72.1 (7.4) | 0.001 |
BMIa, kg/m2, mean (SD) | 268 | 27.3 (4.5) | 28.1 (5.0) | 0.393 |
Smoking habits | ||||
Never smoker n (%) | 102 | 58 (38.4) | 54 (30.3) | 0.144 |
Ex or current smoker n (%) | 195 | 93 (61.6) | 101 (69.7) | |
Pack/years mean (SD) | 144 | 24 (14.3) | 24.2 (14) | 0.851 |
Lung function tests | ||||
FEV1b, L, mean (SD) | 286 | 2.18 (0.71) | 2.20 (0.60) | 0.833 |
FEV1, % predicted, mean (SD) | 288 | 80.1 (20.6) | 75 (15.3) | 0.040 |
FVCc, L, mean (SD) | 278 | 2.75 (0.89) | 2.73 (0.77) | 0.844 |
FVC, % predicted, mean (SD) | 283 | 79.3 (19.2) | 70.5 (13.5) | < 0.001 |
DLCOd, % predicted, mean (SD) | 238 | 54.7 (14.2) | 47.3 (14.5) | < 0.001 |
Country | ||||
Finland | 152 | 107 (68.6) | 45 (28.8) | < 0.001 |
Sweden | 160 | 49 (31.4) | 111 (71.2) | |